On-demand webinar: ZEISS Lightfield 4D for high-content tumor microtissue screening

From reliable and scalable 3D models to quantitative insights.

“Not the results we hoped for” – Novartis’ heart study shows no benefit

Novartis’ drug candidate pelacarsen, aimed at a well‑known cardiovascular risk factor, failed to reduce the risk of heart attack, stroke and cardiovascular deat...

FDA Breakthrough Device Designation lifts Neola shares

Lund-based Neola Medical has been granted the FDA’s Breakthrough Device Designation for Neola, the company’s medical device for continuous lung monitoring in pr...

Astra Zeneca receives US approval for Etcamah

The pharmaceutical company Astra Zeneca has received accelerated FDA approval for Etcamah in combination with a CDK4/6 inhibitor for advanced HR-positive, HER2-...

Dialysis company hit with $15M bill after massive patient data breach

A cyberattack last year exposed the personal data of millions of patients at dialysis provider DaVita. Now the bill has arrived for the company: 15 million dollars in damages.

Sweden takes new steps to tackle oestrogen shortages

Sweden has struggled with shortages of oestrogen medicines for years, forcing women going through the menopause to switch products or search from pharmacy to ph...

Lithuania accelerates life science ambitions with major cell therapy investment

A new center for cell therapy and personalized medicines has opened in the Lithuanian capital, Vilnius.

BII and GU Ventures collaborate on oligonucleotide project

Denmark’s BioInnovation Institute (BII) and Sweden’s GU Ventures are collaborating through a new cross-border project focused on therapeutic oligonucleotides.

ZEISS elevates ophthalmic workflows at ESCRS with new surgical and digital advancements

ZEISS Medical Technology will showcase its latest portfolio advancements and workflow enhancements for cataract, corneal refractive, and retina, at the European...

AbbVie’s myeloma candidate hits both goals in Phase III

The pharmaceutical company Abbvie's etentamig met both primary endpoints in the Phase III CERVINO study in relapsed or refractory multiple myeloma.

SGS webinar on IVDR & MDR certification process

She will lead Unilabs in the Nordics

Unilabs has appointed Ellen Gijsbers as General Manager Nordics.

IRLAB CEO to step down

Kristina Torfgård will step down as CEO of Swedish pharmaceutical company IRLAB Therapeutics in the first quarter of 2027, the company announced.

Novartis reshapes biologics business – 130 jobs at risk

Novartis is continuing to reshape its European operations. Around 130 jobs could now be cut in Basel as the pharmaceutical giant consolidates its biologics deve...

Chinese approval for Leqembi auto-injector

BioArctic’s partner Eisai has received approval in China for the subcutaneous auto-injector formulation of Leqembi as an initial treatment for early Alzheimer’s...

A turning point for personalized cancer vaccines – ”The field is moving quickly now”

The progress of a new personalised drug candidate for skin cancer is raising great hopes in the research community. ”It strengthens confidence in the entire cla...

Swedish‑developed CT scanner cleared in Europe: “Very exciting”

GE Healthcare’s photon‑counting computed tomography (PCCT) system, Photonova Spectra, has now received CE Mark, enabling the Swedish‑developed technology to be ...

The newborn injection more parents are choosing to decline

A vitamin K injection has long been routine for newborn babies, protecting them against rare but potentially serious bleeding. But in the US, a growing number o...

BTK inhibitor shows efficacy in MS – without liver toxicity

A new MS treatment from Novartis has met its targets in two Phase III studies – without showing the liver-related side effects that have previously characterize...

Norwegian drug developer expands into other Scandinavian markets

After four years, NordicRWE has turned to Sweden and Denmark to broaden its business

CeramTec’s digital transformation

Exclusive interview with Dr. Danny Krautz, CDO of CeramTec.

Orexo CEO on settlement: “Very mixed feelings”

After more than $14m in legal fees and years of uncertainty, Orexo is closing in on a settlement with the US Department of Justice.

News editor for Nordiske Medier's life science and medtech publications

Nordiske Medier bevakar hela den nordiska life science- och läkemedelsmarknaden. Nu söker vi en erfaren och utvecklingsorienterad redaktör som ska leda det oper...

AstraZeneca combination shows promise in advanced lung cancer

AstraZeneca and China's Hutchmed have reported positive phase III results for a combination of their cancer drugs Tagrisso and Orpathys in advanced lung cancer.